(S)-{1-[4-(4-fluoro-phenoxy)-phenylcarbamoyl]-2-hydroxy-1-methyl-ethyl}-carbamic acid tert-butyl ester | 876913-96-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-{1-[4-(4-fluoro-phenoxy)-phenylcarbamoyl]-2-hydroxy-1-methyl-ethyl}-carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[(2S)-1-[4-(4-fluorophenoxy)anilino]-3-hydroxy-2-methyl-1-oxopropan-2-yl]carbamate
• CAS: 876913-96-1
• 化学式: C₂₁H₂₅FN₂O₅
• 分子量: 404.438
• InChiKey: JZOOQPYRCBTZKT-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  96.9
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-{1-[4-(4-fluoro-phenoxy)-phenylcarbamoyl]-2-hydroxy-1-methyl-ethyl}-carbamic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (2S)-2-amino-N-[4-(4-fluorophenoxy)phenyl]-3-hydroxy-2-methylpropanamide
  参考文献：
  名称：

  Synthesis and evaluation of arylalkoxy- and biarylalkoxy-phenylamide and phenylimidazoles as potent and selective sphingosine-1-phosphate receptor subtype-1 agonists

  摘要：

  In pursuit of potent and selective sphingosine-1-phosphate receptor agonists, we have utilized previously reported phenylamide and phenylimidazole scaffolds to explore extensive side-chain modi. cations to generate new molecular entities. A number of designed molecules demonstrate good selectivity and excellent in vitro and in vivo potency in both mouse and rat models. Oral administration of the lead molecule 11c (PPI-4667) demonstrated potent and dose-responsive lymphopenia. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.073
• 作为产物：
  描述：

  tert-butyl (S)-2-(4-hydroxyphenylcarbamoyl)-1-hydroxypropan-2-ylcarbamate 、 4-氟苯硼酸 在 吡啶 、 copper diacetate 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-{1-[4-(4-fluoro-phenoxy)-phenylcarbamoyl]-2-hydroxy-1-methyl-ethyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Synthesis and evaluation of arylalkoxy- and biarylalkoxy-phenylamide and phenylimidazoles as potent and selective sphingosine-1-phosphate receptor subtype-1 agonists

  摘要：

  In pursuit of potent and selective sphingosine-1-phosphate receptor agonists, we have utilized previously reported phenylamide and phenylimidazole scaffolds to explore extensive side-chain modi. cations to generate new molecular entities. A number of designed molecules demonstrate good selectivity and excellent in vitro and in vivo potency in both mouse and rat models. Oral administration of the lead molecule 11c (PPI-4667) demonstrated potent and dose-responsive lymphopenia. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.073

文献信息

• Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
  申请人：Saha K. Ashis

  公开号：US20060135786A1

  公开（公告）日：2006-06-22

  The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.

  本发明涉及调节S1P1受体活性的化合物，使用这些化合物治疗与S1P1受体信号传导相关的疾病，并包括这些化合物的药物组合物。
• Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity
  申请人：Saha K. Ashis

  公开号：US20080064662A1

  公开（公告）日：2008-03-13

  The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.

  本发明涉及调节S1P1受体活性的化合物，使用这些化合物治疗与S1P1受体信号有关的疾病，并包括这些化合物的制药组合物。
• COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS
  申请人：Eli Lilly & Company

  公开号：EP1984360A2

  公开（公告）日：2008-10-29
• US7241812B2
  申请人：——

  公开号：US7241812B2

  公开（公告）日：2007-07-10
• [EN] COMPOUNDS AND METHODS FOR MODULATING FXR<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR MODULER FXR
  申请人：LILLY CO ELI

  公开号：WO2007092751A2

  公开（公告）日：2007-08-16

  [EN] Compounds of formula. wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
  [FR] L'invention concerne des composés de la formule (1) dont les variables sont définies dans la description ainsi que leurs compositions pharmaceutiques et procédés d'utilisation, utiles pour traiter la dyslipidémie et les troubles correspondants.